EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kruse, J. A
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kruse, J. A
Evidence-Based Medicine 2004; 9:111
© 2004 BMJ Publishing Group Ltd.


Therapeutics

Review: metformin does not increase risk of lactic acidosis or increase lactate levels in type 2 diabetes

Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003;163:2594–602.[Abstract/Free Full Text]

Q In patients with type 2 diabetes mellitus, what is the risk of fatal and non-fatal lactic acidosis associated with metformin compared with placebo or other glucose lowering therapies? Does metformin increase lactate levels?

Clinical impact ratings GP/FP/Primary care ******{star} IM/Ambulatory care ******{star} Internal medicine ******{star} Endocrine ******{star}

Key Words: diabetes mellitus (type II) • acidosis (lactic) • metformin

The first 150 words of the full text of this article appear below.

METHODS
Data sources: the Cochrane Library, Medline, Reactions, and EMBASE/Excerpta Medica (up to March 2002); references of identified articles and reviews; abstracts of clinical conferences; and authors of relevant studies and manufacturers of metformin.

Study selection and assessment: randomised controlled trials (RCTs) or cohort studies >=1 month in duration that compared metformin, alone or in combination in other treatments, with placebo or another glycaemic lowering intervention for type 2 diabetes. Methodological quality was assessed using criteria that considered randomisation procedure, blinding, and withdrawals and dropouts.

Outcomes: fatal lactic acidosis, non-fatal lactic acidosis, and blood lactate levels for metformin compared with placebo or other non-biguanide therapies, and for metformin compared with phenformin.

MAIN RESULTS
194 studies (126 RCTs and 68 cohort studies, n = 56 692, mean age 57 y, 61% men) met the selection criteria. Mean trial duration was 2.1 years. Metformin was administered in daily doses of 1–3 g and was titrated . . . [Full text of this article]

James A Kruse, MD

Wayne State University School of Medicine
Detroit, Michigan, USA







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd.